Emergence of Vancomycin Resistance inStaphylococcus aureus
Open Access
- 18 February 1999
- journal article
- case report
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 340 (7) , 493-501
- https://doi.org/10.1056/nejm199902183400701
Abstract
Since the emergence of methicillin-resistant Staphylococcus aureus, the glycopeptide vancomycin has been the only uniformly effective treatment for staphylococcal infections. In 1997, two infections due to S. aureus with reduced susceptibility to vancomycin were identified in the United States. We investigated the two patients with infections due to S. aureus with intermediate resistance to glycopeptides, as defined by a minimal inhibitory concentration of vancomycin of 8 to 16 μg per milliliter. To assess the carriage and transmission of these strains of S. aureus, we cultured samples from the patients and their contacts and evaluated the isolates. The first patient was a 59-year-old man in Michigan with diabetes mellitus and chronic renal failure. Peritonitis due to S. aureus with intermediate resistance to glycopeptides developed after 18 weeks of vancomycin treatment for recurrent methicillin-resistant S. aureus peritonitis associated with dialysis. The removal of the peritoneal catheter plus treatment with rifampin and trimethoprim–sulfamethoxazole eradicated the infection. The second patient was a 66-year-old man with diabetes in New Jersey. A bloodstream infection due to S. aureus with intermediate resistance to glycopeptides developed after 18 weeks of vancomycin treatment for recurrent methicillin-resistant S. aureus bacteremia. This infection was eradicated with vancomycin, gentamicin, and rifampin. Both patients died. The glycopeptide-intermediate S. aureus isolates differed by two bands on pulsed-field gel electrophoresis. On electron microscopy, the isolates from the infected patients had thicker extracellular matrixes than control methicillin-resistant S. aureus isolates. No carriage was documented among 177 contacts of the two patients. The emergence of S. aureus with intermediate resistance to glycopeptides emphasizes the importance of the prudent use of antibiotics, the laboratory capacity to identify resistant strains, and the use of infection-control precautions to prevent transmission.Keywords
This publication has 56 references indexed in Scilit:
- National Nosocomial Infections Surveillance (NNIS) Report, data summary from October 1986–April 1996, issued May 1996American Journal of Infection Control, 1996
- Prevention of central venous catheter-related coagulase-negative staphylococcal sepsis in neonatesThe Journal of Pediatrics, 1994
- Prevention of gram-positive sepsis in neonates weighing less than 1500 gramsThe Journal of Pediatrics, 1994
- Benefit of Prophylaxis by Intravenous Systemic Vancomycin in Granulocytopenic Patients: A Prospective, Randomized Trial among 59 PatientsActa Haematologica, 1993
- Lack of effect of changing needles on contamination of blood culturesThe Pediatric Infectious Disease Journal, 1990
- Vancomycin, Ticarcillin, and Amikacin Compared with Ticarcillin-Clavulanate and Amikacin in the Empirical Treatment of Febrile, Neutropenic Children with CancerNew England Journal of Medicine, 1988
- VancomycinMayo Clinic Proceedings, 1987
- Emergence of Vancomycin Resistance in Coagulase-Negative StaphylococciNew England Journal of Medicine, 1987
- A Randomized Trial Comparing Ceftazidime Alone with Combination Antibiotic Therapy in Cancer Patients with Fever and NeutropeniaNew England Journal of Medicine, 1986
- Pediatric surgical infection and antibiotic usageThe Pediatric Infectious Disease Journal, 1985